Administration and management

两种蛋白质，人血浆BuChE和重组人BuChE均处于高级开发阶段 作为保护免受化学战剂伤害的潜在的杀虫剂。这些蛋白质反应迅速， 以有效地消除血流中的毒物，但是它们需要相对大的 大量的蛋白质来提供保护。确定一种基于蛋白质的药物的挑战是， 需要更少的材料，同时提供具有增强的用户接受度的优点的改进的保护 不容忽视最近与该中心合作的实验室已经确定了几个人类 酶，对氧磷酶（PON）和丁酰胆碱酯酶的突变体，可以催化所有的水解， 神经毒剂因此，这些是用于预防性施用以提供保护的极好候选物。 恐怖袭击的第一反应者或文职维和环境中的军事部队， 不对称威胁如果通过静脉注射，它也可以作为一种快速起效的治疗药物 一部分暴露在神经毒剂下的平民的解毒剂初步研究表明 这些目标是可行的，也是可以实现的。这种药物的成本/效益比是这样的， 一个成功的优秀候选人，并有可能成为一系列新型药物中的第一个。 该中心将协调旨在增强天然催化剂的整体努力， 这些人类酶的活性，以创造一个可行的候选人过渡到临床试验的进展 在五年内。这将解决国家保护平民目标中的一个关键差距 恐怖分子发起的化学武器袭击。 目前针对恐怖分子接触化学神经毒剂的医疗保护仅限于接触后 治疗我们将鉴定和开发一种能够提供快速和有效的抗肿瘤药物的人类蛋白质， 长期持久的预防性保护，防止接触化学战神经毒剂。这种药物将 实现向广大民众提供更好的保护， 恐怖分子发动的化学武器袭击

Two proteins, human plasma BuChE, and a recombinant human BuChE are both in advanced development as potential prophylacitcs for protecting against chemical warfare agents. These proteins react rapidly and stoiciometrically to effectively scavenge the poisons in the blood stream but they require relatively large amounts of protein to provide protection. The challenge of identifying a protein based drug that would require less material while providing improved protection with the advantage of enhanced user acceptance cannot be ignored. Recent efforts the laboratories alinged with the Center have identified several human enzymes, paraoxonase (PON) and a mutant of butyrylcholinesterase that can catalyze the hydrolysis of all nerve agents. As such these are excellent candidate for prophylactic administration to provide protection for first responders to a terrorist attack or military forces in a civilian peacekeeping setting subject to an asymmetric threat. If it were administered intravenously it could also serve as a rapid-onset therapeutic antidote to a segment of the civilian popuation exposed to nerve agents. Preliminary studies have shown that these objectives are both feasible and obtainable. The cost/benefit ratio of such a drug is such that it is an excellent candidate for success and has the potential to be the first in a series of a novel class of drugs. The center will coordinate the overall effort directed toward the enhancement of the the native catalytic activity of these human enzymes to create a viable candidate for transition to advancement to clinical trials within a five year period. This will address a critical gap in the national goal of protecting the civilian population against a terrorist-initiated chemical weapons attack. Current medical protection against chemical nerve agent exposure by terrorists is limited to post exposure treatment. We will identify and develop for clinical testing a human protein capable of providing rapid and long lasting prophylactic protection against exposure to chemical warfare nerve agents. Such a drug will address the critical national goal of providing improved protection to the general population against a terrorist-initiated chemical weapons attack.